Browse

Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.

Trump's pandemic preparedness nominee testifies, the "fang-to-pharmacy" pipeline, and more health news from Morning Rounds

Amylyx Pharmaceuticals will soon read out results from a study evaluating a new treatment for a rare endocrine disorder, a pivotal moment for patients and the company.